PRKCE: Protein kinase C epsilon type
Calcium-independent, phospholipid- and diacylglycerol (DAG)- dependent serine/threonine-protein kinase that plays essential roles in the regulation of multiple cellular processes linked to cytoskeletal proteins, such as cell adhesion, motility, migration and cell cycle, functions in neuron growth and ion channel regulation, and is involved in immune response, cancer cell invasion and regulation of apoptosis.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on PRKCE, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Other 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| KAI-1678 | Phase 2 | Kai Pharmaceuticals | Other | InhibitorProtein kinase C epsilon inhibitor | 0 |
- Acute myeloid leukemia0.56
- Hypertensive disorder0.52
- Open-angle glaucoma0.50
- Coronary artery disorder0.49
- Mast cell leukemia0.47
- Systemic mastocytosis0.47
- Neurodegenerative disease0.47
- Mastocytosis0.46
- Abnormality of the skeletal system0.45
- Metabolic disease0.44
- Coronary atherosclerosis0.44
- Essential hypertension0.44
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3582, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q02156, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets